PLERIXAFOR, Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM
VX21-CTX001-161
Phase 3 small_molecule active
Quick answer
PLERIXAFOR, Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN, FILGRASTIM for Transfusion-dependent β-thalassemia (TDT), Severe sickle cell disease (SCD) is a Phase 3 program (small_molecule) at Vertex Pharmaceuticals (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Vertex Pharmaceuticals (Ireland) Limited
- Indication
- Transfusion-dependent β-thalassemia (TDT), Severe sickle cell disease (SCD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active